Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Sun Pharmaceutical Industries
Large Cap•43,000 Employees•IPO 1994
Current Price
₹1825.90
13.1 (0.72%)Updated
Today's Range
1818.1
₹1825.90
1843
52 Week Range
52W Low₹1548.00
52W High₹1851.20
₹1825.90
Downside17.95%
Upside1.39%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹4,12,052.11 Cr
Market Cap
Total market value of companyP/E Ratio
37.75
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
4.92
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹45.45
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.02%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
20.20%
ROCE
Return on Capital Employed. >15% is goodNet Margin
19.21%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
23.75%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
9.87%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
9.47%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
1.16%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.03
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹300.99
Book Value
Net asset value per shareDividend Yield
0.91%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
54.50%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Robust profitability with 29.70% Operating Profit Margin and 20.20% ROCE.
- •Consistent quarterly sales growth of 9.47% indicates strong market demand.
Weaknesses
5 points- •P/E ratio of 40.80 is relatively high, suggesting potential overvaluation.
- •Modest quarterly profit variation of 1.16% indicates operational efficiency challenges.
Opportunities
4 points- •Global pharmaceutical market growth driven by aging population and chronic diseases.
- •Strong financial base allows investment in R&D for new drug development.
Threats
3 points- •Highly competitive pharmaceutical sector from established players like Cipla.
- •Stringent and evolving global regulatory landscapes pose operational risks.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1889.70 | +₹63.80 | +3.49% |
| R3 | ₹1864.80 | +₹38.90 | +2.13% |
| R2 | ₹1853.90 | +₹28.00 | +1.53% |
| R1 | ₹1839.90 | +₹14.00 | +0.77% |
| PIVOT | ₹1829.00 | 3.10 | 0.17% |
| CURRENT | ₹1825.90 | - | - |
| S1 | ₹1765.20 | -₹60.70 | -3.32% |
| S2 | ₹1790.10 | -₹35.80 | -1.96% |
| S3 | ₹1804.10 | -₹21.80 | -1.19% |
| S4 | ₹1815.00 | -₹10.90 | -0.60% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+8.5% vs avg
2.51M
(11 Mar 2026)Delivery %+1.0% vs avg
68.5%
(11 Mar 2026)Avg Volume (20D)20-day average
2.31M
(11 Feb - 11 Mar)Avg Delivery %Trend ↓
67.6%
(11 Feb - 11 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Torrent Pharmaceuticals Ltd
1.44L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Abbott India Ltd
1.79 %
Peer Comparison
| Company Name |
|---|
 Abbott India Ltd |
 Alkem Laboratories Ltd |
 Aurobindo Pharma Ltd |
 Cipla Ltd |
 Dr Reddys Laboratories Ltd |
 Glenmark Pharmaceuticals Ltd |
 Laurus Labs Ltd |
 Lupin Ltd |
 Mankind Pharma Ltd |
 Torrent Pharmaceuticals Ltd |
 Zydus Lifesciences Ltd |
About
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Limited (Sun Pharma) is a global pharmaceutical company headquartered in Mumbai, India. Established in 1983, the company operates across the entire pharmaceutical value chain, encompassing research and development, manufacturing, and marketing of a diverse portfolio of pharmaceutical products.
Sun Pharma's core business revolves around the development, manufacturing, and marketing of both branded and generic formulations. Their product portfolio spans a wide range of therapeutic areas, including but not limited to central nervous system treatments, dermatological products, cardiovascular medications, oncology drugs, and treatments for neuropsychiatric, gastroenterological, and infectious diseases. They also cater to various other therapeutic segments such as diabetology, pain management, respiratory ailments, and women's health.
A significant aspect of Sun Pharma's operations is the production of Active Pharmaceutical Ingredients (APIs). These APIs are the fundamental building blocks of many medications and Sun Pharma manufactures a substantial range, including those used in anti-cancer therapies, peptide-based drugs, steroids, hormones, and immunosuppressants. This vertical integration allows for greater control over the supply chain and cost-effectiveness.
The company offers its formulations in various forms, including tablets, capsules, injectables, inhalers, topical applications (ointments and creams), and liquids. Beyond generic medications, Sun Pharma also markets specialty medications and antiretroviral drugs, along with over-the-counter (OTC) products. This diversification helps cater to a broad spectrum of patient needs and market segments.
In essence, Sun Pharma's business model is built upon a foundation of comprehensive pharmaceutical capabilities, covering the entire spectrum from API manufacturing to the marketing of finished dosage forms across various therapeutic categories. Their global presence and diversified product portfolio position them as a major player in the worldwide pharmaceutical industry.
COMPANY FACTS - SUNPHARMA
Registered Address
Sun House,, CTS No. 201 B/1,, Western Express Highway,Goregaon (E),
Mumbai
MAHARASHTRA
IN
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 43,000
IPO Date: 01/01/1994
MANAGEMENT - SUNPHARMA
Mr. Dilip Shanghvi
Chairman, Managing Director, Executive Director
Mr. C. S. Muralidharan
Chief Financial Officer
Mr. Aalok Shanghvi
Whole-time Director, Executive Vice-President, Emerging Markets, Global generic R&D, Global BD (Generics Segment) & API
Mr. Anoop Deshpande
Compliance Officer, Company Secretary
Dr. Pawan Goenka
Lead Non-Executive Independent Director
Mr. Sudhir Valia
Non-Executive and Non-Independent Director
Mr. Sanjay Asher
Non-Executive Independent Director
Ms. Rama Bijapurkar
Non-Executive Independent Director
Shri. Gautam Doshi
Non-Executive Independent Director
Mr. Rolf Hoffmann
Non-Executive Independent Director
Dr. Abhishek Sharma
Investor Relations Officer
Investor Questions Answered
Sun Pharmaceutical Industries Ltd (SUNPHARMA) Stock FAQs
Get answers to the most common questions about Sun Pharmaceutical Industries Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1,825.9. Today, the stock has gained by ₹13.10 (0.72%), trading in a range of ₹1,818.1 to ₹1,843. The stock opened at ₹1,823 with a trading volume of 25,10,495 shares.
Sun Pharmaceutical Industries Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,12,052.11 crores, P/E ratio of 37.75, ROE of 7.02%, and ROCE of 20.20%. The dividend yield stands at 0.91%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1,851.2, while the 52-week low is ₹1,548. Currently trading at ₹1,825.9, the stock is 91.7% away from its 52-week low and 1.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Sun Pharmaceutical Industries Ltd stock at ₹1,825.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.75 and P/B ratio of N/A. Today's performance shows a gain of 0.72%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Sun Pharmaceutical Industries Ltd offers a dividend yield of 0.91%, which means for every ₹100 invested at the current price of ₹1,825.9, you can expect to receive approximately ₹0.91 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Sun Pharmaceutical Industries Ltd's key financial metrics include: P/E Ratio: 37.75, P/B Ratio: N/A, ROE: 7.02%, ROCE: 20.20%, Dividend Yield: 0.91%, EPS: ₹45.45, Book Value: ₹300.99, Debt-to-Equity: 0.03, and Current Ratio: N/A. The company's market cap stands at ₹4,12,052.11 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Sun Pharmaceutical Industries Ltd stock opened at ₹1,823 and is currently trading at ₹1,825.9, showing a gain of ₹13.10 (0.72%). The intraday high is ₹1,843 and low is ₹1,818.1. The trading volume stands at 25,10,495 shares, indicating strong market participation today.
Sun Pharmaceutical Industries Ltd has a Price-to-Earnings (P/E) ratio of 37.75, which means investors are willing to pay ₹37.75 for every ₹1 of earnings. With an EPS of ₹45.45, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Sun Pharmaceutical Industries Ltd has a market capitalization of ₹4,12,052.11 crores, making it a large-cap company. Market cap is calculated by multiplying the current stock price (₹1,825.9) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Sun Pharmaceutical Industries Ltd has a book value of ₹300.99 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,825.9, which is 506.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Sun Pharmaceutical Industries Ltd has a Return on Equity (ROE) of 7.02% and Return on Capital Employed (ROCE) of 20.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Sun Pharmaceutical Industries Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Sun Pharmaceutical Industries Ltd has a debt-to-equity ratio of 0.03, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Sun Pharmaceutical Industries Ltd has an Earnings Per Share (EPS) of ₹45.45, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,825.9 and P/E ratio of 37.75, investors are paying 37.75 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Sun Pharmaceutical Industries Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Sun Pharmaceutical Industries Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Sun Pharmaceutical Industries Ltd stock, consider: 1) Fundamental Analysis - Review P/E (37.75), ROE (7.02%), debt-to-equity (0.03), and growth rates. 2) Technical Analysis - Check 52-week range (₹1548.00 - ₹1851.20), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1825.90) with book value (₹300.99) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Sun Pharmaceutical Industries Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,825.9 is 182490x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Sun Pharmaceutical Industries Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1548.00 - ₹1851.20). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.03 indicates leverage. 4) Liquidity Risk - Based on trading volume of 25,10,495 shares. 5) Valuation Risk - P/E of 37.75 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Sun Pharmaceutical Industries Ltd operates in the industry with key metrics: P/E ratio of 37.75, ROE of 7.02%, market cap of ₹4,12,052.11 crores, and dividend yield of 0.91%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.03), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Sun Pharmaceutical Industries Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,825.9, with a 52-week range of ₹1548.00 to ₹1851.20. Based on fundamentals like P/E (37.75), ROE (7.02%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Sun Pharmaceutical Industries Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1825.90. 2) Fundamental Deterioration - Declining ROE (currently 7.02%), increasing debt (D/E: 0.03), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Sun Pharmaceutical Industries Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.91%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu